Patents by Inventor Guohan Yang
Guohan Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8962549Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.Type: GrantFiled: January 13, 2014Date of Patent: February 24, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Guohan Yang, Ton That Hai, Bennett Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
-
Publication number: 20140128445Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.Type: ApplicationFiled: January 13, 2014Publication date: May 8, 2014Applicants: Baxter Healthcare SA, Baxter International Inc.Inventors: Guohan Yang, Ton That Hai, Bennett Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
-
Patent number: 8653131Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.Type: GrantFiled: August 21, 2009Date of Patent: February 18, 2014Assignees: Baxter Healthcare S.A., Baxter International Inc.Inventors: Guohan Yang, Ton That Hai, Bennett P. Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
-
Patent number: 8642532Abstract: This invention is a method of using a class of excipients for protein formulation to reduce and/or eliminate protein aggregation in solutions or solids. This class of compounds contains carbonyl group(s) to form Schiff base(s) with amino groups of proteins and also contains moieties to keep protein molecules spatially separated. This method has never been disclosed anywhere in the literature.Type: GrantFiled: November 17, 2008Date of Patent: February 4, 2014Inventor: Guohan Yang
-
Publication number: 20140024582Abstract: The invention provides methods for improving the physical and chemical stabilities of therapeutic proteins in solutions by reducing or eliminating protein degradation, aggregation and precipitation using small molecule stabilizing agents such as proline, arginine and/or compounds capable of forming a Schiff bond with amino groups of the protein. The invention further provides liquid formulations of a monomeric insulin stabilized by one of more stabilizing agents such as proline, arginine and/or acetone. Also provided are methods of making and using the stabilized monomeric insulin formulations.Type: ApplicationFiled: March 21, 2013Publication date: January 23, 2014Applicant: GENECOPOEIA, INC.Inventor: Guohan YANG
-
Publication number: 20110046052Abstract: This invention is a method of using a class of excipients for protein formulation to reduce and/or eliminate protein aggregation in solutions or solids. This class of compounds contains carbonyl group(s) to form Schiff base(s) with amino groups of proteins and also contains moieties to keep protein molecules spatially separated. This method has never been disclosed anywhere in the literature.Type: ApplicationFiled: November 17, 2008Publication date: February 24, 2011Inventor: Guohan Yang
-
Patent number: 7875467Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.Type: GrantFiled: November 21, 2007Date of Patent: January 25, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Anand A. Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
-
Publication number: 20100048483Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.Type: ApplicationFiled: August 21, 2009Publication date: February 25, 2010Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Guohan Yang, Ton T. Hai, Bennett Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
-
Publication number: 20090029349Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.Type: ApplicationFiled: November 21, 2007Publication date: January 29, 2009Applicant: Siemens Medical Solutions DiagnosticsInventors: Anand A. Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
-
Publication number: 20080305557Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.Type: ApplicationFiled: November 21, 2007Publication date: December 11, 2008Applicant: Siemens Medical Solutions DiagnosticsInventors: Anand Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
-
Patent number: 7319041Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.Type: GrantFiled: September 27, 2002Date of Patent: January 15, 2008Assignee: Siemens Medical Solutions DiagnosticInventors: Anand Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
-
Publication number: 20070281031Abstract: An active agent and a non-polymeric polyanionic compound are allowed to be associated with a microparticle containing an anionic macromolecule and an anionic polymer in the presence of a crosslink activator. In a non-limiting example, the non-polymeric polyanionic compound is a polyanionic amino acid such as aspartic acid or glutamic acid. The microparticle can be used for modified release of the active agent in vitro and/or in vivo.Type: ApplicationFiled: June 1, 2006Publication date: December 6, 2007Inventor: Guohan Yang
-
Publication number: 20040063147Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.Type: ApplicationFiled: September 27, 2002Publication date: April 1, 2004Applicant: BAYER CORPORATIONInventors: Anand Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
-
Publication number: 20030143607Abstract: Highly hydrophilic non-nucleosidic tags with multiple labels are provided for use in nucleic acid probes. The tags are branched structures having a phosphodiester backbone, which have the advantages of a small dimensional size and high hydrophilicity. After the tag is labeled, its high negative charge and minimal size help to keep the carriers away from DNA or RNA molecules, due to repulsion between negative charges. Non-specific intercalation and steric hindrance are therefore minimized, and the hydrophobicity, if any of reporter molecules is reduced. The probes are used in place of conventionally labeled oligonucleotides for a variety of hybridization reactions.Type: ApplicationFiled: December 18, 2002Publication date: July 31, 2003Inventors: Guohan Yang, Donna M. Ford, Say-Jong Law, John E. Monahan, Todd B. Sells
-
Patent number: 6504019Abstract: Highly hydrophilic non-nucleosidic tags with multiple labels are provided for use in nucleic acid probes. The tags are branched structures having a phosphodiester backbone, which have the advantages of a small dimensional size and high hydrophilicity. After the tag is labeled, its high negative charge and minimal size help to keep the carriers away from DNA or RNA molecules, due to repulsion between negative charges. Non-specific intercalation and steric hindrance are therefore minimized, and the hydrophobicity, if any of reporter molecules is reduced. The probes are used in place of conventionally labeled oligonucleotides for a variety of hybridization reactions.Type: GrantFiled: March 21, 2001Date of Patent: January 7, 2003Assignee: Bayer CorporationInventors: Guohan Yang, Donna M. Ford, Say-Jong Law, John E. Monahan, Todd B. Sells
-
Publication number: 20020015953Abstract: Highly hydrophilic non-nucleosidic tags with multiple labels are provided for use in nucleic acid probes. The tags are branched structures having a phosphodiester backbone, which have the advantages of a small dimensional size and high hydrophilicity. After the tag is labeled, its high negative charge and minimal size help to keep the carriers away from DNA or RNA molecules, due to repulsion between negative charges. Non-specific intercalation and steric hindrance are therefore minimized, and the hydrophobicity, if any of reporter molecules is reduced. The probes are used in place of conventionally labeled oligonucleotides for a variety of hybridization reactions.Type: ApplicationFiled: March 21, 2001Publication date: February 7, 2002Inventors: Guohan Yang, Donna M. Ford, Say-Jong Law, John E. Monahan, Todd B. Sells